Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

By K. Noda, Y. Nishiwaki, M. Kawahara, S. Negoro, T. Sugiura, A. Yokoyama, M. Fukuoka, K. Mori, Koshiro Watanabe, T. Tamura and 2 more. New England Journal of Medicine, 2002

1,362 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/5b0730e5d7f1ab85673ab46df64ae8155be97b83

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Ronald P. Miller
2. R. Tadagavadi
3. W. B. Reeves
4. G. Ramesh
5. T. Roberts
6. B. Chabner

Citations in the corpus

• Chemotherapy and the war on cancer (2005, background): “Later, this agent would also be used to treat lung and ovarian cancer”
• Mechanisms of Cisplatin Nephrotoxicity (2010, background): “cancer [7], small-cell [8] and non-small cell lung cancer [9], ovarian [10,11] and cervical cancer [12], bladder cancer [13] and others [14].”